



The United States of America



RECEIVED

OCT 04 2002

TECH CENTER 1600/2800

The Commissioner of
Patents and Trademarks

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.

If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.

If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extension.

Acting Commissioner of Patents and Trademarks

Attest

United States Patent [19]

Smith et al.



US005863927A

[11] Patent Number: 5,863,927
[45] Date of Patent: Jan. 26, 1999

[54] DEXTROMETHORPHAN AND AN OXIDASE INHIBITOR FOR TREATING INTRACTABLE CONDITIONS

[75] Inventors: Richard Alan Smith, La Jolla; Jonathan M. Licht, San Diego, both of Calif.

[73] Assignee: Center for Neurologic Study, La Jolla, Calif.

[21] Appl. No.: 464,792

[22] PCT Filed: Sep. 22, 1994

[86] PCT No.: PCT/US94/10771

§ 371 Date: Sep. 19, 1996

§ 102(e) Date: Sep. 19, 1996

[87] PCT Pub. No.: WO96/09044

PCT Pub. Date: Mar. 28, 1996

[51] Int. Cl.⁶ A61K 31/44; A61K 31/265; A61K 31/135

[52] U.S. Cl. 514/289; 514/305; 514/491;

[58] Field of Search 514/649; 514/651; 514/652; 514/654 514/289, 305, 514/491, 652, 654, 649, 651

[56] References Cited

U.S. PATENT DOCUMENTS

4,316,888	2/1982	Nelson	424/127
5,166,207	11/1992	Smith	514/270
5,206,248	4/1993	Smith	514/289
5,350,756	9/1994	Smith	514/289
5,352,683	10/1994	Mayer et al.	514/289
5,366,980	11/1994	Smith	514/289
5,502,058	3/1996	Mayer et al.	514/289

OTHER PUBLICATIONS

Dickenson, A.H., "A cure for wind up: NMDA receptor antagonists as potential analgesics," *Trends in Pharm. Sci.* 11: 307-309 (1990).

Dickenson, A.H., et al, "Dextromethorphan and levorphanol on dorsal horn nociceptive neurones in the rat," *Neuropharmacology* 30: 1303-1308 (1991).

France, C.P., et al. "Analgesic Effects of Phencyclidine-Like Drugs in Rhesus Monkeys," *J. Pharmacol. Exp. Therapeutics* 250: 197-201 (1989).

Mao, J., et al, "Intrathecal treatment with dextrophan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy," *Brain Research* 605: 164-168 (1993).

McCarthy, J.P., "Some less familiar drugs of abuse," *Med. J. Australia* 1971 (2): 1078-1081 (1971).

McQuay, H.J., et al, "Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design," *Pain* 59: 127-133 (1994).

Tortella, F.C., et al, "Dextromethorphan and neuromodulation: old drug coughs up new activities," *Trends in Pharm. Sci.* 10: 501-507 (1989).

Zhang et al., "Dextromethorphan: Enhancing its Systemic Availability by Way of Low-dose Quinidine-mediated Inhibition of Cytochrome P4502D6," *Clin. Pharm. ? Ther.* 51(6): 647-655 (1992).

Primary Examiner—Phyllis G. Spivack
Attorney, Agent, or Firm—Patrick D. Kelly; Christine M. Bellas

[57] ABSTRACT

Methods are disclosed for increasing the effectiveness of dextromethorphan in treating chronic or intractable pain, for treating tinnitus and for treating sexual dysfunction comprising administering dextromethorphan in combination with a therapeutically effective dosage of a debrisoquin hydroxylase inhibitor. A preferred combination is dextromethorphan and the oxidative inhibitor quinidine.

(22 Claims, 1 Drawing Sheet)